OP0065 Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial

V Rantalaiho,K Puolakka,M Leirisalo-Repo,J Martikainen,H Kautiainen

doi:10.1136/annrheumdis-2014-eular.3265

OP0065 Initial Infliximab is not Cost-Effective in Otherwise Actively Treated Early Rheumatoid Arthritis. the 2-Year Follow-Up Results of the Randomized Clinical Neo-Raco Trial

V Rantalaiho, K Puolakka + Show 3 more

https://doi.org/10.1136/annrheumdis-2014-eular.3265

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2014

Affiliation: Tampere University, Tampere University Hospital, South Karelia Central Hospital, Helsinki University Hospital, Kuopio University Hospital

#Strict Remission #Disease Modifying Antirheumatic Drugs + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundIn most early rheumatoid arthritis (RA) patients, early remission and a non-progressive state of disease can be achieved when an initial treatment with a triple combination of disease modifying antirheumatic...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.